ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Clinton Administration Issues Research Misconduct Policy.

December 8, 2000

NIH Awards 24 More Grants For Women’s Health Initiative

October 14, 1994

NIH to Hold Meeting On Faculty Design

February 2, 1996

Ethics Commission Acknowledges Weak Case For Mandatory Patient Compensation

April 23, 1982

IOM Committee Will Probe Duke Scandal Together With Other “Omics” Case Studies

January 7, 2011

Nomograms 66% Correct In Predicting Outcome For Brachytherapy, Study Finds

September 28, 2001